Table 2.
Association of clinical and genetic factors with overall survival
| Factor | Group | n | Median survival (d) | p value |
|---|---|---|---|---|
| Age (y) | > 70 | 20 | 660 (413–876) | 0.00030 |
| ≤ 70 | 8 | 333 (105–432) | ||
| Sex | Male | 17 | 475 (385–735) | 0.39 |
| Female | 11 | 412 (175–841) | ||
| Pre-KPS | > 70 | 16 | 409 (314–611) | 0.060 |
| ≤ 70 | 12 | 689 (432–881) | ||
| EOR | Gross total resection | 25 | 475 (406–689) | 0.50 |
| Partial resection | 3 | 432 (105-NA) | ||
| BCNU wafer | No | 19 | 660 (381–876) | 0.11 |
| Yes | 9 | 441 (149–611) | ||
| Bevacizumab | No | 20 | 453.5 (335–674) | 0.75 |
| Yes | 8 | 565 (314–881) | ||
| Region 1 | Methylated | 13 | 674 (406–876) | 0.27 |
| Unmethylated | 8 | 422 (105–881) | ||
| Region 2 | Methylated | 13 | 841 (413–961) | 0.0026 |
| Unmethylated | 8 | 363 (105–660) | ||
| Region 3 | Methylated | 3 | 876 (406-NA) | 0.65 |
| Unmethylated | 18 | 521.5 (331–735) |
Pre-KPS Preoperative Karnofsky Performance Status